USFDA updates Camzyos label to reduce echocardiography monitoring requirements, contraindications: Bristol Myers Squibb Ruchika Sharma18 April 2025 11:00 AM ISTPrinceton: Bristol Myers Squibb has announced that the U.S. Food and Drug Administration (FDA) has updated the U.S. Prescribing Information for...
Mavacamten Misses Primary Endpoints in Phase 3 Trial for Non-Obstructive HCM Dr. Kamal Kant Kohli17 April 2025 8:00 AM ISTBristol Myers Squibb announced that mavacamten did not achieve statistical significance in meeting the dual primary endpoints in the Phase 3...
Bristol Myers Squibb heart disease drug fails to meet main goals in late-stage study Ruchika Sharma16 April 2025 9:30 AM ISTPrinceton: Bristol Myers Squibb has announced the Phase 3 ODYSSEY-HCM trial evaluating Camzyos (mavacamten) for the treatment of adult...
Bristol Myers Squibb bags European Commission nod for heart disease treatment Camzyos Ruchika Sharma27 Jun 2023 11:31 AM ISTPrinceton: Bristol Myers Squibb has announced that the European Commission (EC) has approved CAMZYOS (mavacamten, 2.5 mg, 5 mg, 10 mg,...
Bristol Myers Squibb gets positive CHMP opinion recommending nod for CAMZYOS for treatment of Symptomatic Obstructive Hypertrophic Cardiomyopathy Ruchika Sharma30 April 2023 12:15 PM ISTPrinceton: Bristol Myers Squibb has announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency...
Bristol Myers Squibb gets USFDA nod for obstructive hypertrophic cardiomyopathy drug Camzyos Ruchika Sharma1 May 2022 10:30 AM ISTPrinceton: Bristol Myers Squibb has announced that the U.S. Food and Drug Administration (USFDA) has approved Camzyos (mavacamten, 2.5 mg, 5...
